linkstream2 microblog

Atlantic article…

September 27, 2026

Americans Don’t Understand Who’s Rich

The small-business owners with curiously large fortunes

By Owen Zidar and Eric Zwick
https://www.theatlantic.com/ideas/2026/09/everywhere-millionaires-tax-code/688584/ Note S v C tax incentives

QT:{{”
Last year’s One Big Beautiful Bill Act… made
permanent a 20 percent deduction that effectively lowers the top tax rate for private-business owners from 37 percent to 30 percent. And it preserved a loophole that lets business owners in most of the country, but not salaried employees, deduct their state and local taxes in full…. A loophole that lets private-business owners avoid Medicare taxes has
similarly been justified as a break for the little guy.
“}}

Posted in - | Leave a Comment »
Tags: taxes, tbg, therm0mg

A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models – PMC

September 26, 2026

https://pmc.ncbi.nlm.nih.gov/articles/PMC11738990/
QT:{{”
Using AI-driven methodology, we generated INS018_055, a small-molecule TNIK inhibitor, which exhibits desirable drug-like properties and anti-fibrotic activity across different organs in vivo through oral, inhaled or topical administration…. Its safety and tolerability as well as pharmacokinetics were validated in a randomized,
double-blinded, placebo-controlled phase I clinical trial
(NCT05154240) involving 78 healthy participants.
“}}

Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., Aladinskiy, V., Ivanenkov, Y., Polykovskiy, D., Fu, Y., Babin, E., Qiao, J., Liang, X., Mou, Z., Wang, H., . . . Zhavoronkov, A. (2024). A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology, 43(1), 63–75.
https://doi.org/10.1038/s41587-024-02143-0

Posted in SciLit | Leave a Comment »
Tags: drugtarget, insilico, to

Omar Baker, M.D., on the future of peptides

September 26, 2026

https://www.newbeauty.com/view/fda-peptide-regulations-explained

Omar Baker, M.D., explains the future of peptides in
Peptides are everywhere right now, but knowing what’s safe and effective can be difficult. To help navigate this rapidly growing space, Elysium Health Chief Medical Officer Omar Baker, M.D., F.A.A.P., recently spoke with NewBeauty following a key FDA advisory committee meeting. Dr. Baker broke down what new regulatory updates mean for patients, why high purity standards matter, and how physician oversight ensures you get real benefits safely. At Elysium, we believe the future of longevity medicine relies on rigorous science, clear standards, and expert clinical guidance: All peptide therapies available at The Elysium Longevity Institute will be prescribed by licensed providers and dispensed by U.S. pharmacies. The featured products include compounded products which have not been approved by the FDA. The FDA does not verify the safety, effectiveness, or quality of compounded drugs. Read Dr. Baker’s full breakdown on where peptide therapy goes from here.

Posted in - | Leave a Comment »

NYTimes: The Most Important Longevity Term You’ve Probably Never Heard Of

September 26, 2026

https://www.nytimes.com/2026/08/26/well/intrinsic-capacity-longevity-measure.html?smid=nytcore-ios-share

Posted in - | Leave a Comment »
Tags: longevity

US finally gets new sunscreen molecule, bemotrizinol

September 26, 2026

• A long-awaited ingredient: For the first time since 1996, the US is getting a new UV filter, bemotrizinol. Widely used outside the US, it offers strong protection against both UVA and UVB rays and is less likely to be absorbed into the bloodstream.
• Why did it take so long? Unlike in Europe, where UV filters are regulated as cosmetics, the US treats them as medications—requiring extensive and expensive trials. Consumers can expect the products containing bemotrizinol around September.

https://cen.acs.org/business/specialty-chemicals/fda-approves-new-sunscreen-molecule-bemt/104/web/2026/06

Posted in - | Leave a Comment »
Tags: bemotrizinol, keyabbrev